VCYT

$33.48

Post-MarketAs of Mar 17, 8:00 PM UTC

Veracyte, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$33.48
Potential Downside
53.3%
Whystock Fair Value$15.64
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDiagnostics & Research

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Dec...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.66B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
40.83
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.96
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
5.34%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
7.63

Recent News

Simply Wall St.
Mar 3, 2026

Veracyte (VCYT) Valuation Check After Strong 2025 Earnings And Reaffirmed 2026 Growth Outlook

Veracyte (VCYT) just delivered fourth quarter and full year 2025 results that combined higher revenue with much stronger profitability, while also reaffirming its 2026 guidance for double digit growth tied to its cancer testing portfolio. See our latest analysis for Veracyte. Even with the strong 2025 earnings and reaffirmed 2026 outlook, Veracyte’s recent share price performance has been weak in the short term, with a 30 day share price return of 5.44% and a 90 day share price return of...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 26, 2026

Veracyte Q4 Earnings Beat Estimates, Revenues Grow Y/Y, Stock Rises

VCYT posts a 47% y/y Q4 earnings jump and 18.5% revenue growth, beats estimates, lifts margins and sees shares rise after hours.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Moby
Feb 26, 2026

Veracyte, Inc. Q4 2025 Earnings Call Summary

Moby summary of Veracyte, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
MarketBeat
Feb 26, 2026

Veracyte Q4 Earnings Call Highlights

Veracyte (NASDAQ:VCYT) management said fourth-quarter results capped “another outstanding year” of execution, highlighted by double-digit revenue growth, expanding profitability and progress toward multiple new product launches planned for 2026. Fourth-quarter and full-year performance Chief Execut

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Feb 26, 2026

Veracyte Inc (VCYT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Veracyte Inc (VCYT) reports robust financial performance with a 19% revenue increase and prepares for significant product launches in 2026.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.